Results 151 to 160 of about 172,502 (268)

Targeting PLD3 Reverses the Immunosuppressive Niche by Reprogramming Tumor‐Associated Macrophages and Potentiates Antitumor Immunity

Advanced Science, EarlyView.
PLD3 activates the lysosomal‐AKT‐NF‐κB axis to drive cellular senescence in macrophages, establishing an immunosuppressive TME by limiting the infiltration of cytotoxic T, NK, and NKT cells, which confers resistance to anti‐PD‐1 therapy. Abrine inhibits PLD3 expression, restoring antitumor immunity and synergizing with anti‐PD‐1 treatment.
Xingtu Qin, Qiong Li, Xuemei Xu, Yuhan Wu, Yin Zhu, Jieqiong Wu, Yuan Fang, Qiubei Chen, Shuyang Wang, Jiang Yu, Yaping Ye, Hongli Jiao   +11 more
wiley   +1 more source

Vascular access in Pará: clinical and epidemiological aspects of patients on renal replacement therapy at the largest specialist center in Pará state, Brazil. [PDF]

J Vasc Bras
Dos Reis JMC, Silva IB, Monteiro MGPB, Guerra MMNB, da Costa DL, Rodrigues FFP, de Andrade MC.   +6 more
europepmc   +1 more source

A Non‐Canonical Core Transcriptional Regulatory Circuit Orchestrates Chromatin Reprogramming to Drive Osimertinib Resistance in Non‐Small Cell Lung Cancer

Advanced Science, EarlyView.
A non‐canonical core transcriptional regulatory circuit, composed of ID3, SMAD3, and NR2F2, drives Osimertinib resistance in non‐small cell lung cancer through super‐enhancer‐mediated activation of EPAS1, which couples neuroendocrine differentiation with ferroptosis evasion.
Aochu Liu, Zhenguo Liu, Lizhen Jiang, Andong Huang, Xinqing Lin, Xinyue Li, Bingyuan Liu, Shiwen Hu, Qiang Pan, Junjun Huang, Liyuan Yin, Liling Jiang, Wei Yi, Wenjun Mao, Yueyuan Zheng, Xianping Shi   +15 more
wiley   +1 more source

Proceedings of the University of Alabama at Birmingham Continuous Renal Replacement Therapy Academy (2023-2024): Managing De-Escalation of Acute Renal Replacement Therapy and Optimizing Drug Dosing during Renal Replacement Therapy Transitions. [PDF]

Kidney360
Beaubien-Souligny W, Thompson Bastin M, Teixeira JP, Cerda J, Connor MJ, Dijanic Zeidman A, Garimella PS, Juncos L, Lopez-Ruiz A, Mehta R, Reis T, Rizo-Topete L, Silver SA, Da Silva JR, Speer R, Vijayan A, Wells C, Wille K, Yessayan L, Tolwani A, Neyra JA.   +20 more
europepmc   +1 more source

Senescent Cell Derived Artificial Vesicle‐Based Senolytic Sonovaccine Platform with Augmented Lymph Node Delivery and Antigen Cross‐Presentation Efficacy

Advanced Science, EarlyView.
A senolytic sonovaccine platform (SenoVac) is developed, in which senescent cell‐derived vesicles serve as broad senescent cell antigen reservior. The “2‐step” click chemistry strategy for effective lymph node delivery, and ultrasound‐triggered endosomal escape to boost cross‐presentation, ensures efficient senescent cell clearance and disease ...
Liang Zhang, Yubo Lai, Jia Wang, Lingling Liu, Jieyuan An, Mi Qu, Yuan Liang, Bijun Tan, Guodong Yang, Xuekang Yang, Lijun Yuan   +10 more
wiley   +1 more source

Predictive value of FST for renal replacement therapy in patients with acute kidney injury: a meta-analysis. [PDF]

Sci Rep
Zhao C, Zhang Z, Wang X, Zhang T, Guo S, Xin Y, Zhu G, Hu Z.   +7 more
europepmc   +1 more source

Herba Lysimachiae Polysaccharide‐Modified Selenium Nanoparticles Alleviate Oxidative Injury in Kidney Stones via TOMM22‐Regulated Mitophagy Activation

Advanced Science, EarlyView.
HLP‐SeNPs, a Lysimachia christinae polysaccharide‐modified selenium nanoparticle, treat kidney stones by downregulating TOMM22 expression, which reduces PINK1 translocation into mitochondria and promotes its retention on the outer mitochondrial membrane.
Junyi Yang, Guoruiyu Lyu, Wenlong Wan, Dongfeng Yuan, Jiabo Li, Yongqi Wang, Baokang Wang, Zhilong Ma, Yuanyuan Yang, Yang Xun, Xiao Yu   +10 more
wiley   +1 more source

Summary of best evidence for nutritional management in adult patients undergoing continuous renal replacement therapy. [PDF]

Front Med (Lausanne)
Jia L, Wei J, Zhu K, Wang X, Sun Y.
europepmc   +1 more source

Mitochondrial Carrier SLC25A13 Drives Ferroptosis Resistance and Immune Evasion via a STAT3–IFI6 Circuit in Breast Cancer

Advanced Science, EarlyView.
SLC25A13 is identified as an immunometabolic driver of triple‐negative breast cancer that sustains ferroptosis resistance and immune evasion through a STAT3–IFI6 circuit. Pharmacologic degradation of SLC25A13 restores ferroptosis sensitivity and enhances anti‐PD‐1 efficacy, highlighting a strategy to convert immune‐cold tumors into immunotherapy ...
Yingze Zhu, Yuhan Tang, Yingcui Chen, Zhuoqi Zhang, Yige Lu, Xinyue Wang, Qiyuan Shi, Wenhui Zhao, Hui Pang   +8 more
wiley   +1 more source

Prognostic Factors of 30-Day In-Hospital Mortality in Critically Ill Patients Receiving Continuous Renal Replacement Therapy. [PDF]

J Nurs Res
Lee HJ, Kim T, Lee H, Lee Y, Heo J, Son YJ.   +5 more
europepmc   +1 more source